Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria.  Journal of the American Society of Nephrology.  29:1615-1623. 2018
2018 Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line.  Redox Biology.  15:207-215. 2018
2017 The L530R variation associated with recurrent kidney stones impairs the structure and function of TRPV5.  Biochemical and Biophysical Research Communications.  492:362-367. 2017
2017 Steatorrhea and Hyperoxaluria in Severely Obese Patients Before and After Roux-en-Y Gastric Bypass.  Gastroenterology.  152:1055-1067.e3. 2017
2017 An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria.  Journal of the American Society of Nephrology.  28:494-503. 2017
2016 RNA interference in the treatment of renal stone disease: Current status and future potentials.  International Journal of Surgery.  36:713-716. 2016
2016 Ascorbic acid intake and oxalate synthesis.  Urolithiasis.  44:289-297. 2016
2016 Monocyte Mitochondrial Function in Calcium Oxalate Stone Formers.  Urology.  93:224.e1-224.e6. 2016
2016 Effects of alanine: Glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay 2016
2016 Oxalate Concentrations in Human Gastrointestinal Fluid 2016
2016 Molecular Modeling of the Structural and Dynamical Changes in Calcium Channel TRPV5 Induced by the African-Specific A563T Variation.  Biochemistry.  55:1254-1264. 2016
2016 Lowering urinary oxalate excretion to decrease calcium oxalate stone disease.  Urolithiasis.  44:27-32. 2016
2016 Metabolism of 13C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase 2016
2016 Oxalate formation from glyoxal in erythrocytes.  Urology.  88:226.e11-226.e15. 2016
2015 Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3 2015
2015 Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria.  Biochemical Journal.  466:273-281. 2015
2015 A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5′UTR causing primary hyperoxaluria type II 2015
2012 Hydroxyproline metabolism in mouse models of primary hyperoxaluria 2012
2012 Metabolism of [ 13C 5]hydroxyproline in vitro and in vivo: Implications for primary hyperoxaluria 2012
2012 The association of cardiovascular disease and metabolic syndrome with nephrolithiasis.  Current Opinion in Urology.  22:154-159. 2012
2012 Multibacterial growth from a surgical renal stone culture: a case report and literature review..  Reviews in Urology.  14:108-114. 2012
2011 Variability in urinary oxalate measurements between six international laboratories.  Nephrology Dialysis Transplantation.  26:3954-3959. 2011
2011 Difficulties with access in percutaneous renal surgery 2011
2011 Re: Oxalate and sucralose absorption in idiopathic calcium oxalate stone formers 2011
2011 Impact of dietary calcium and oxalate, and oxalobacter formigenes colonization on urinary oxalate excretion 2011
2011 Metabolism of primed, constant infusions of [1,2-13C 2] glycine and [1-13C1] phenylalanine to urinary oxalate 2011
2011 Oxalate and sucralose absorption in idiopathic calcium oxalate stone formers.  Urology.  78:475.e9-475.e13. 2011
2006 Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2.  Nephrology Dialysis Transplantation.  21:2292-2295. 2006
2005 Genetic and dietary factors in urinary citrate excretion 2005
2005 Mitochondrial hydroxyproline metabolism: Implications for primary hyperoxaluria.  American Journal of Nephrology.  25:171-175. 2005
2005 Dietary oxalate loads and renal oxalate handling 2005
2004 Glycolate and glyoxylate metabolism in HepG2 cells 2004
2004 The impact of dietary oxalate on kidney stone formation.  Urolithiasis.  32:311-316. 2004
2001 (L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1.  BJU International.  88:858-862. 2001
2001 Contribution of dietary oxalate to urinary oxalate excretion.  Kidney International.  59:270-276. 2001
2000 Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2).  Human Genetics.  107:176-185. 2000
2000 Role of diet in the therapy of urolithiasis.  Urologic Clinics of North America.  27:255-268. 2000
1997 Genes in idiopathic calcium oxalate stone disease.  World Journal of Urology.  15:186-194. 1997
1997 Pathways of hepatic oxalate synthesis and their regulation.  American Journal of Physiology.  272. 1997
1997 Pathways of hepatic oxalate synthesis and their regulation..  American Journal of Physiology.  272:C289-C294. 1997
1997 The effects of (L)-2-oxothiazolidine-4-carboxylate on urinary oxalate excretion 1997
1996 Re: Family pattern of idiopathic hypercalciuria and its subtypes 1996
1995 Dietary oxalate and its intestinal absorption.  Scanning microscopy.  9:1109-1120. 1995
1995 Glucagon increases urinary oxalate excretion in the guinea pig..  American Journal of Physiology.  269:E568-E574. 1995
1995 Genetic Factors in Calcium Oxalate Stone Disease 1995
1995 Glucagon increases urinary oxalate excretion in the guinea pig 1995
1995 Measurement of urinary oxalate and citrate by capillary electrophoresis and indirect ultraviolet absorbance 1995
1993 The absence of glyxylate cycle enzymes in rodent and embryonic chick liver 1993
1993 Relationship of protein intake to urinary oxalate and glycolate excretion.  Kidney International.  44:366-372. 1993
1992 Recent developments in assays for taurine, hypotaurine and some metabolic precursors.  Advances in human genetics.  315:423-428. 1992
1992 Tetrodotoxin protects against acute ischemic renal failure in the rat 1992
1989 Selective elevation of urinary enzyme levels after extracorporeal shock wave lithotripsy 1989
1987 Failure of leukotriene B4 to translocate calcium across phosphatidylcholine membranes.  Cell Calcium.  8:449-454. 1987

Principal Investigator On

Investigator On

  • Interdisciplinary Training In Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019 - 2024
  • Kidney Undergraduate Research Experience (KURE)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Obesity and Endogenous Oxalate Synthesis  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • PRedoctoral Interdisciplinary Training in Renal Physiology and MEdIcIne (PRIME)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by CHINOOK THERAPEUTICS, INC 2019 - 2022
  • Glycolate Metabolism and Kidney Oxalate  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2017 - 2022
  • The Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2020 - 2022
  • Hypercalciuria and TRPV6-Mediated Active Calcium Reabsorption in the Proximal Tubule  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2017 - 2022
  • Oxalobacter Formigenes Colonization and Oxalate Excretion in Calcium Oxalate Kidney Stone Disease  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2017 - 2022
  • Monocyte Mitochondrial Dysfunction and Kidney Stone Disease  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2016 - 2021
  • Influence of Obesity on Endogenous Oxalate Synthesis  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2020
  • Influence of Obesity on Endogenous Oxalate Synthesis - Project  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2020
  • Private Grant  awarded by ALNYLAM PHARMACEUTICALS, INC. 2018 - 2019
  • Hydroxyproline Dehydrogenase and Glycolate Oxidase as Targets for Lowering Urinary Oxalate Excretion  awarded by WAKE FOREST BAPTIST HEALTH 2017 - 2018
  • Inhibition of Oxalate Synthesis by RNA Interference Rare Kidney Stone Consortium  awarded by MAYO CLINIC 2017 - 2018
  • Oxalate Handling and Oxalobacter Formigenes Colonization in a Mouse Model  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2013 - 2017
  • Private Grant  awarded by ALNYLAM PHARMACEUTICALS, INC. 2014 - 2015
  • Hereditary Causes of Nephrolitiasis and Kidney Failure  awarded by MAYO CLINIC 2012 - 2014

    • Education And Training

  • Doctor of Philosophy in Biochemistry, The Australian National University 1978

    • Full Name

  • Ross Holmes